Zomedica Corp. [AMEX: ZOM] loss -1.21% on the last trading session, reaching $0.21 price per share at the time. The company report on September 13, 2022 that Zomedica Announces Launch of Free T4 Assay for Truforma(R) Diagnostic Platform.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering novel diagnostic and therapeutic products for companion animals, today announced the commercial launch of its newest assay – Free T4 (fT4) – for the TRUFORMA In-Clinic Biosensor Testing Platform.
“The proprietary point-of-care TRUFORMA free T4 assay brings a valuable diagnostic tool into the veterinary clinic for the first time,” said Larry Heaton, Zomedica’s Chief Executive Officer. “This new assay for the TRUFORMA instrument is an example of Zomedica’s ongoing commitment to meet the needs of clinical veterinarians in ways that promote both patient and practice health.”.
Zomedica Corp. represents 979.90 million in outstanding shares, while the company has a total market value of $213.62 million with the latest information. ZOM stock price has been found in the range of $0.21 to $0.22.
If compared to the average trading volume of 15.57M shares, ZOM reached a trading volume of 5238378 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Zomedica Corp. [ZOM]:
The Average True Range (ATR) for Zomedica Corp. is set at 0.02, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 17.65. The Price to Book ratio for the last quarter was 0.78, with the Price to Cash per share for the same quarter was set at 0.19.
Trading performance analysis for ZOM stock
Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.91. With this latest performance, ZOM shares dropped by -20.34% in over the last four-week period, additionally sinking by -36.93% over the last 6 months – not to mention a drop of -60.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 38.05, with the RSI for the last a single of trading hit 35.08, and the three-weeks RSI is set at 40.57 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.2709, while it was recorded at 0.2155 for the last single week of trading, and 0.2877 for the last 200 days.
Zomedica Corp. [ZOM]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Zomedica Corp. [ZOM] shares currently have an operating margin of -517.14 and a Gross Margin at +46.32. Zomedica Corp.’s Net Margin is presently recorded at -444.78.
Return on Equity for this stock declined to -11.01, with Return on Assets sitting at -10.61.
Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 42.40 and a Current Ratio set at 43.50.
An analysis of insider ownership at Zomedica Corp. [ZOM]
There are presently around $20 million, or 11.30% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 44,076,354, which is approximately 8.543% of the company’s market cap and around 1.48% of the total institutional ownership; BLACKROCK INC., holding 11,353,498 shares of the stock with an approximate value of $2.41 million in ZOM stocks shares; and CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., currently with $2.37 million in ZOM stock with ownership of nearly 0.054% of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 30 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 9,087,394 shares. Additionally, 51 investors decreased positions by around 28,378,510 shares, while 38 investors held positions by with 57,120,100 shares. The mentioned changes placed institutional holdings at 94,586,004 shares, according to the latest SEC report filing. ZOM stock had 12 new institutional investments in for a total of 3,336,548 shares, while 27 institutional investors sold positions of 5,957,933 shares during the same period.